Julia M. Shifman

Prof. Julia M. Shifman

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AEAriel Erijman
Ariel Erijman
EREran Rosenthal
Eran Rosenthal
Julia M. ShifmanJulia M. Shifman
Julia M. Shifman
Protein-protein interactions (PPI) in nature are conveyed by a multitude of binding modes involving various surfaces, secondary structure elements and intermolecular interactions. This diversity results in PPI binding affinities that span more than nine orders of magnitude. Several early studies attempted to correlate PPI binding affinities to various structure-derived features with limited success. The growing number of high-resolution structures, the appearance of more precise methods for measuring binding affinities and the development of new computational algorithms enable more thorough investigations in this direction. Here, we use a large dataset of PPI structures with the documented binding affinities to calculate a number of structure-based features that could potentially define binding energetics. We explore how well each calculated biophysical feature alone correlates with binding affinity and determine the features that could be used to distinguish between high-, medium- and low- affinity PPIs. Furthermore, we test how various combinations of features could be applied to predict binding affinity and observe a slow improvement in correlation as more features are incorporated into the equation. In addition, we observe a considerable improvement in predictions if we exclude from our analysis low-resolution and NMR structures, revealing the importance of capturing exact intermolecular interactions in our calculations. Our analysis should facilitate prediction of new interactions on the genome scale, better characterization of signaling networks and design of novel binding partners for various target proteins.

1 February 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
VAValeria Arkadash
Valeria Arkadash
GYGal Yosef
Gal Yosef
JSJason Shirian
Jason Shirian
ICItay Cohen
Itay Cohen
YHYuval Horev
Yuval Horev
NPNiv Papo
Niv Papo
Degradation of the extracellular matrices in the human body is controlled by matrix metalloproteinases (MMPs), a family of more than 20 homologous enzymes. Imbalance in MMP activity can result in many diseases, such as arthritis, cardiovascular diseases, neurological disorders, fibrosis, and cancers. Thus, MMPs present attractive targets for drug design and have been a focus for inhibitor design for as long as 3 decades. Yet, to date, all MMP inhibitors have failed in clinical trials because of their broad activity against numerous MMP family members and the serious side effects of the proposed treatment. In this study, we integrated a computational method and a yeast surface display technique to obtain highly specific inhibitors of MMP-14 by modifying the natural non-specific broad MMP inhibitor protein N-TIMP2 to interact optimally with MMP-14. We identified an N-TIMP2 mutant, with five mutations in its interface, that has an MMP-14 inhibition constant (Ki) of 0.9 pm, the strongest MMP-14 inhibitor reported so far. Compared with wild-type N-TIMP2, this variant displays ∼900-fold improved affinity toward MMP-14 and up to 16,000-fold greater specificity toward MMP-14 relative to other MMPs. In an in vitro and cell-based model of MMP-dependent breast cancer cellular invasiveness, this N-TIMP2 mutant acted as a functional inhibitor. Thus, our study demonstrates the enormous potential of a combined computational/directed evolution approach to protein engineering. Furthermore, it offers fundamental clues into the molecular basis of MMP regulation by N-TIMP2 and identifies a promising MMP-14 inhibitor as a starting point for the development of protein-based anticancer therapeutics.

12 March 2018 in FEBS Letters
Verified
Journal Article
Closed access
PDF file
JSJason Shirian
Jason Shirian
VAValeria Arkadash
Valeria Arkadash
ICItay Cohen
Itay Cohen
TSTamila Sapir
Tamila Sapir
EREvette S. Radisky
Evette S. Radisky
Julia M. ShifmanJulia M. Shifman
Julia M. Shifman

1 May 2016 in Trends in Biochemical Sciences
Verified
Journal Article
Closed access
LRLior Rosenfeld
Lior Rosenfeld
MHMichael Heyne
Michael Heyne
Julia M. ShifmanJulia M. Shifman
Julia M. Shifman
NPNiv Papo
Niv Papo

13 October 2020 in Science Signaling
Verified
Journal Article
Closed access
TDThillaivillalan Dhanaraman
Thillaivillalan Dhanaraman
SSSwati Singh
Swati Singh
RKRyan C. Killoran
Ryan C. Killoran
ASAnamika Singh
Anamika Singh
XXXingjian Xu
Xingjian Xu
MSMatthew J. Smith
Matthew J. Smith
RASSF proteins interact with distinct GTPase partners to regulate downstream Hippo and p53 signaling.

19 July 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ILIsabel Leung
Isabel Leung
ADAyelet Dekel
Ayelet Dekel
Julia M. ShifmanJulia M. Shifman
Julia M. Shifman
SSSachdev Sidhu
Sachdev Sidhu
Significance: Although ubiquitin (Ub) interactions are essential to cell physiology, there is a paucity of functional data on how Ub recognizes the diverse enzymes in the Ub proteasome system. We subjected two high-affinity Ub variants (Ubvs) to saturation scanning analysis to obtain comprehensive information on how they interact with Ub-specific proteases (USPs). Our data reveal the molecular details of how individual Ubv side chains mediate weak but specific interactions with these proteases. We find that the enzymes are recognized by similar functional epitopes on the Ubvs, and that these epitopes interact with a region that is conserved across the human USP family, suggesting that Ub may interact with many USPs by using a common core functional epitope.